Incannex Healthcare (IXHL) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing oral synthetic cannabinoid and psilocybin drug candidates for chronic diseases with unmet needs, including sleep apnea, anxiety, and inflammatory diseases.

• Lead programs include IHL-42X (dronabinol and acetazolamide) for obstructive sleep apnea, PSX-001 (synthetic psilocybin with psychotherapy) for generalized anxiety disorder, and IHL-675A (cannabidiol and hydroxychloroquine) for inflammation.

• No revenue generated to date; future revenue depends on successful regulatory approval and commercialization of drug candidates.

• Incorporated in Delaware in July 2023 following redomiciliation from Australia.

Financial performance and metrics

• As of October 18, 2024, 17,642,832 shares of common stock outstanding, held by 4,899 stockholders.

• Aggregate market value of common stock held by non-affiliates is $30.59 million, based on 12,961,669 shares at $2.36 per share.

• No significant revenue expected in the foreseeable future.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement.